Table 3.
Immune response elicited by the 2-dose schedules and by the licensed 3-dose schedule, by age stratum, one month after the last vaccine dose and at Month 24 (ATP immunogenicity cohort, initially seronegative subjects)
| Antigen | Age (years) | Vaccine schedule | Group | N | GMT (95% CI), EU/mL |
| One month after last active vaccine dose | |||||
| HPV-16 | 9–14 | 3-dose | 20/20F M0,1,6 | 67 | 22,261 (18,034, 27,480) |
| 2-dose | 20/20F M0/6 | 65 | 11,067 (9,190, 13,328) | ||
| 2-dose | 40/40F M0,6 | 61 | 15,304 (12,855, 18,221) | ||
| 2-dose | 40/40F M0,2 | 75 | 7,442 (6,238, 8,878) | ||
| 15–19 | 3-dose | 20/20F M0,1,6 | 60 | 12,858 (9,696, 17,051) | |
| 2-dose | 20/20F M0/6 | 62 | 8,442 (6,895, 10,336) | ||
| 2-dose | 40/40F M0,6 | 66 | 11,061 (9,035, 13,541) | ||
| 2-dose | 40/40F M0,2 | 70 | 5,153 (4,246, 6,254) | ||
| 20–25 | 3-dose | 20/20F M0,1,6 | 51 | 7,971 (5,766, 11,020) | |
| 2-dose | 20/20F M0/6 | 51 | 5,673 (4,377, 7,354) | ||
| 2-dose | 40/40F M0,6 | 46 | 8,307 (6,533, 10,564) | ||
| 2-dose | 40/40F M0,2 | 56 | 4,809 (3,886, 5,952) | ||
| HPV-18 | 9–14 | 3-dose | 20/20F M0,1,6 | 68 | 7,399 (6,033, 9,073) |
| 2-dose | 20/20F M0/6 | 64 | 5,510 (4,646, 6,535) | ||
| 2-dose | 40/40F M0,6 | 62 | 8,155 (6,671, 9,970) | ||
| 2-dose | 40/40F M0,2 | 70 | 5,095 (4,288, 6,140) | ||
| 15–19 | 3-dose | 20/20F M0,1,6 | 61 | 4,845 (3,740, 6,277) | |
| 2-dose | 20/20F M0/6 | 63 | 5,142 (4,354, 6,072) | ||
| 2-dose | 40/40F M0,6 | 69 | 6162 (4,996, 7,601) | ||
| 2-dose | 40/40F M0,2 | 68 | 2,986 (2,385, 3,740) | ||
| 20–25 | 3-dose | 20/20F M0,1,6 | 53 | 3,676 (2,898, 4,664) | |
| 2-dose | 20/20F M0/6 | 49 | 3,523 (2,514, 4,937) | ||
| 2-dose | 40/40F M0,6 | 53 | 4,230 (3,346, 5,349) | ||
| 2-dose | 40/40F M0,2 | 54 | 2,742 (2,031, 3,701) | ||
| Month 24 | |||||
| HPV-16 | 9–14 | 3-dose | 20/20F M0,1,6 | 61 | 3,606 (2,738, 4,750) |
| 2-dose | 20/20F M0/6 | 64 | 1,702 (1,416, 2,045) | ||
| 2-dose | 40/40F M0,6 | 56 | 2,274 (1,868, 2,768) | ||
| 2-dose | 40/40F M0,2 | 68 | 1,170 (931, 1,471) | ||
| HPV-18 | 9–14 | 3-dose | 20/20F M0,1,6 | 63 | 1,102 (845, 1,436) |
| 2-dose | 20/20F M0/6 | 63 | 702 (563, 876) | ||
| 2-dose | 40/40F M0,6 | 57 | 980 (765, 1,255) | ||
| 2-dose | 40/40F M0,2 | 64 | 450 (352, 575) | ||
ATP, according-to-protocol; CI, confidence interval; EU, ELISA unit; GMT, geometric mean titer; N, number of evaluable seronegative subjects in the ATP immunogenicity cohort at Month 7, or Month 24, respectively.